
Mayne Pharma Stock Jumps 86% After Richter Takeover Deal
Why is Mayne Pharma stock up today?
Mayne Pharma (MYX) stock jumped about 86% to A$5.97 on Tuesday after Hungary's Gedeon Richter agreed to buy the drugmaker for A$6.40 a share in cash, a takeover valuing it at about A$604M.
Key numbers
| Offer price (cash) | A$6.40+99.4% vs Nov 16 close |
|---|---|
| Deal value | A$604Mabout US$408M |
| Mayne share price | A$5.97+86% on Tuesday |
| Premium to 30-day average price | 124%per Inside FMCG |
| Top-3 holders backing deal | 22.14%of Mayne shares |
What happened
Mayne Pharma (MYX) stock jumped about 86% to A$5.97 on Tuesday after Hungary's Gedeon Richter agreed to buy the drugmaker for A$6.40 a share in cash, a takeover valuing it at about A$604M. Richter will pay with its own cash, so the deal has no financing condition. The price is 99.4% above Monday's closing price and 124% above the average price over the past 30 days. Mayne sells women's health and skin medicines in the US, which Richter wants to grow. Shareholders vote in late January, and completion is targeted for March 2027.
Why it matters
Mayne Pharma shareholders are set to receive A$6.40 in cash for each share, nearly double the price the day before. The deal is not final yet. It needs approval from shareholders, a court and Australia's foreign investment regulator (FIRB). Mayne's last takeover bid, from US firm Cosette, was blocked by the Australian government on national-interest grounds, so regulator approval is a key step.
Who this affects
- MarketneutralLow impact
- Small effect on the wider market; Mayne holders gain.
- CompanybullishHigh impact
- Mayne shareholders get a 99.4% premium; company loses independence.
- CompetitorsneutralLow impact
- US women's health rivals face a better-funded Richter.
- IndustryneutralLow impact
- Overseas drugmakers keep seeking US women's health assets.
Mayne Pharma vs Organon, Amneal, Perrigo
How we got here
Australia blocks US firm Cosette's A$7.40-a-share takeover of Mayne on national-interest grounds
Mayne shares close at about A$3.21, the base for Richter's 99.4% premium
Richter and Mayne announce the A$6.40 cash deal; Mayne shares jump about 86%
What to watch
- Mayne shareholder vote on the scheme, plus the independent expert's report on whether the deal is fair2027-01
- Foreign investment (FIRB) approval and completion of Mayne's international unit sale to Evaris PharmaQ1 2027
- Court hearing and targeted deal completion2027-03
Educational content only. Not investment advice.
More briefsAll briefs →

Oil Falls to $92 as Glut Fears Outweigh Hormuz Attacks
Brent crude (BZ=F) slipped 0.5% Tuesday while Vice President Vance said Iran war won't last two more years.

Trump-Kim Meeting Odds Jump to 18% After APEC Summit Hint
Traders on Polymarket added 13 points in a day after Trump said he may meet Kim at China's APEC summit.
Chevron Nears $5B Deal for Gulf of Mexico Producer Beacon
Chevron (CVX) is reported to be close to buying most of Blackstone-backed Beacon, which holds 70 Gulf leases.